BioXcel Therapeutics (BTAI) Change in Inventory (2022 - 2026)
BioXcel Therapeutics' (BTAI) quarterly Change in Inventory came in at -$222000.0 in Q1 2026, down 500.0% year-on-year from $55500.0 in Q1 2025, and down 184.41% quarter-over-quarter from $263000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Change in Inventory (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Change in Inventory history runs 5 years deep, the most recent figure standing at -$222000.0 for Q1 2026.
- On a quarterly basis, Change in Inventory fell 500.0% year-over-year to -$222000.0 in Q1 2026; TTM through Mar 2026 was -$142000.0, a 92.1% increase from a year earlier, with the FY2025 full-year figure at $43000.0, up 103.28% from the prior year.
- Change in Inventory retreated to -$222000.0 in Q1 2026 per BTAI's latest filing, from $263000.0 in the prior quarter.
- Across five years, Change in Inventory topped out at $713000.0 in Q2 2022 and bottomed at -$1.2 million in Q3 2024.
- The 5-year median for Change in Inventory is -$27000.0 (2023), against an average of $29411.8.
- Biggest YoY gain for Change in Inventory was 1457.58% in 2024; the steepest drop was 3033.33% in 2024.
- Year by year, Change in Inventory stood at $577000.0 in 2022, then tumbled by 104.68% to -$27000.0 in 2023, then slumped by 3033.33% to -$846000.0 in 2024, then soared by 131.09% to $263000.0 in 2025, then tumbled by 184.41% to -$222000.0 in 2026.
- Per Business Quant, the three latest BTAI Change in Inventory figures stand at -$222000.0 (Q1 2026), $263000.0 (Q4 2025), and -$47000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -93.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 114.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 119.24 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 123.00 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -4.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 | -222,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -222,000.00 |
| Mar 31, 2026 | -222,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Sep 30, 2025 | -47,000.00 |
| Sep 30, 2025 | -47,000.00 |
| Jun 30, 2025 | -136,000.00 |
| Jun 30, 2025 | -136,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Dec 31, 2024 | -846,000.00 |
| Dec 31, 2024 | -846,000.00 |
| Sep 30, 2024 | -1.16 Mn |
| Sep 30, 2024 | -1.16 Mn |
| Jun 30, 2024 | 241,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Dec 31, 2023 | -27,000.00 |